Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 85,906 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Fuchs' Dystrophy, Bullous Keratopathy
Interventions: Prednisolone acetate, Fluorometholone; Drug
Lead sponsor: Price Vision Group; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Postpartum Preeclampsia, Hypertension in Pregnancy
Interventions: Labetalol Oral Tablet, NIFEdipine ER; Drug
Lead sponsor: Nebraska Methodist Health System; Other
Eligibility: 19 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Otitis Media
Interventions: PNCRM9, Placebo comparator; Biological
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 2
States / cities: Bloomington, Minnesota • Minneapolis, Minnesota

Conditions: Psoriasis
Interventions: SFA002; Drug
Lead sponsor: SFA Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Pompano Beach, Florida • Fargo, North Dakota • Philadelphia, Pennsylvania

Conditions: Obstructive Sleep Apnea, Spinal Cord Injuries
Interventions: Mild intermittent hypoxia, Sham protocol, Continuous positive airway pressure (CPAP); Other
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: Hepatitis C Virus Infection
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 20 more

Conditions: Reversible Cerebral Vasoconstriction Syndrome
Interventions: TCD- cerebral blood flow velocities, Headache pain score, Neurological examination, Repeat Neuroimaging, Nimodipine, Verapamil ER; Diagnostic Test · Behavioral · Other + 1 more
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Glioblastoma
Interventions: CART-EGFR-IL13Ra2 Cells; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2039
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
Interventions: Avelumab, Irinotecan, Paclitaxel, Best Supportive Care (BSC); Drug · Other
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 28
States / cities: Denver, Colorado • Pueblo, Colorado • Miami, Florida + 24 more

Conditions: Preterm Birth, Breast Milk Expression, Nutrition Disorder, Infant, Brain Development Abnormality, Neurodevelopmental Disorders
Interventions: Individually targeted fortification; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 1 Day to 21 Days
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dementia
Interventions: Oral Fasudil 90 mg/day, Oral Fasudil 180 mg/day, Oral Placebo; Drug
Lead sponsor: Woolsey Pharmaceuticals; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Stamford, Connecticut • Lakeland, Florida • Miami Lakes, Florida + 3 more

Conditions: Teen Pregnancy Prevention
Interventions: Are You Ready? (AYR), Social Media Awareness Shorts (SMAS); Behavioral
Lead sponsor: The Policy & Research Group; Other
Eligibility: 14 Years to 22 Years
Enrollment: 1,850 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Body Weight
Interventions: Message; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Depression, Hypertension
Interventions: paroxetine, ongoing psychological screening; Drug · Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 25 Years to 65 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Dry Eye Disease
Interventions: Lotemax, Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears), In Vivo Confocal Microscopy (IVCM); Drug · Diagnostic Test
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: transdermal nicotine patch (7mg); Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 45 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Progressive Multiple Sclerosis
Interventions: KYV-101 (Biological) - 0.33 ×10^8 cells, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC), Chemotherapy: fludarabine (FLU); Biological · Drug
Lead sponsor: Bruce Cree; Other
Eligibility: 25 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypoglycemia
Interventions: Insulin, Glucose, Potassium phosphate; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Obesity, Gender, Problem of Aging
Interventions: Cardiopulmonary Exercise Stress Test, Climatic-Controlled Cardiopulmonary Exercise Stress Test, Body Composition Evaluation, Pre-Exercise Risk Assessment; Procedure
Lead sponsor: Freeman-Sheldon Research Group, Inc.; Other
Eligibility: 35 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1972
U.S. locations: 1
States / cities: Buckhannon, West Virginia

Conditions: Parkinson Disease
Interventions: Virtual reality bicycling; Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 45 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: COPD Exacerbation, Care Transitions
Interventions: Virtual at Home Medication Reconciliation Visit(s), Virtual At Home Medication Education Visit(s), COPD advanced practice nurse Inpatient Consult, Inpatient Medication Reconciliation, Post-discharge nurse 48 hour phone follow-up call, Post-discharge follow-up advanced practice nurse outpatient visit; Other · Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: NASH
Interventions: EDP 305; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Multiple Myeloma
Interventions: TTI-622, Daratumumab Hyaluronidase-fihj; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Search by objective public record fields.

Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)

Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial

Maternal Immunization To Prevent Infant Otitis Media

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

Mild Intermittent Hypoxia and Its Multipronged Effect on Sleep Apnea

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

RCVS: The Rational Approach to Diagnosis and Treatment

CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Targeting Human Milk Fortification to Improve Preterm Infant Growth and Brain Development

Fasudil fOr redUcing elopemeNt and Spatial Disorientation

Evaluation of Are You Ready?

Messages and Plans to Increase Gym Utilization

Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients

The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED

Nicotine Patch, Blood Flow and Oxidative Stress Study

A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes

Work-Related Effects of Heat, Activity, and Fat in Middle Aged Men

Immersive Virtual Reality Bicycling for Persons With Parkinson's Disease

Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study

Telehealth Education Leveraging Electronic Transitions Of Care for COPD Patients

A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma